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Oxadiazoles for Covid-19? 
Amelia Carolina Sparavigna
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Oxadiazoles are a class of heterocyclic aromatic chemical compounds, having different isomeric
forms. They appear in a variety of pharmaceutical drugs (among them the antiviral Raltegravir).
Can these drugs have a possible role in the treatment of Covid-19? Or, why can't they be used for?
Torino 22 May 2020, DOI: 10.5281/zenodo.3841079
Several drugs are under investigation of clinical trials to find the best of them in the treatment of
Covid-19  [1].  Some  are  used  to  reduce  the  cytokine  storms,  such  as  Tocilizumab,  others  are
antivirals. In the case of Hydroxychloroquine, an antimalarial, it is used for its anti-inflammatory
effect and also for a possible antiviral effect in patients of Covid-19.
However,  some  drugs  exist,  based  on  Oxadiazole  compounds,  which  have  antimalarial,  anti-
inflammatory and antiviral features. Then, here we want to pose a question: can Oxadiazoles have a
possible role in the treatment of Covid-19? 
Oxadiazoles are a class of heterocyclic aromatic chemical compounds, which are interesting also for
their liquid crystalline phases [2]. In one of their isomeric forms, Oxadiazoles appear in a variety of
pharmaceutical drugs. In particular, in [3] it is told that "compounds containing 1,3,4-Oxadiazole
ring  in  their  structure  are  characterised  by  multidirectional  biological  activity.  Their  anti-
proliferative  effects  associated  with  various  mechanisms,  such  as  inhibition  of  growth  factors,
enzymes, kinases and others, deserve attention. ... In most publications, the most active derivatives
of 1,3,4-Oxadiazole exceeded the effect of reference drugs, so they may become the main new anti-
cancer drugs in the future". In fact, the "Oxadiazole isomers occur in the structure of many drugs,
e.g.,  antitussive  Oxolamine,  antimicrobial  Furamizole,  antiviral  Raltegravir  and  others"  [3].
Moreover,  it  is  also  stressed  that  there  "are  numerous  literature  reports  confirming  the
multidirectional effect of compounds containing the 1,3,4-oxadiazole ring in its structure". We find,
among the others, antimalarial [4], anti-inflammatory [5] and antiviral effect [6,7] (see also [8,9]),
besides anti-cancer properties.
Since Hydroxychloroquine is an antimalarial, and an antimalarial Oxadiazole compound exists, it
could be interesting to test for this drug a possible effect on Sars-Cov-2. The same we can repeat for
the Oxadiazoles having anti-inflammatory and antiviral properties.  
The posed question (can these drugs have a possible role in the treatment of Covid-19?) is therefore
reasonable. Alternatively, why can't Oxadiazoles be used for treatment?
A note on Raltegravir - 23 May 2020.
Raltegravir is an antiretroviral medication used, together with other medication, to treat HIV/AIDS.
According to NIH, currently, there are 332 clinical trials about this drug (no one about Covid-19).
However,  the  following study exists,  given in  Ref.  [10].  For  the  authors  of  the  study entitled
"Targeting SARS-CoV-2: a systematic drug repurposing approach to identify promising inhibitors
against  3C-like  proteinase  and  2′-O-ribose  methyltransferase",  it  was  imperative  "to  identify
promising inhibitors from pre-existing antiviral drugs". They have studied the two druggable targets
mentioned in the tile. They have been selected "due to their indispensable nature in the viral life
cycle". "The selected drug target proteins were screened against an in-house library of 123 antiviral
drugs. Two promising drug molecules were identified for each protein based on their estimated free
energy of binding (ΔG), the orientation of drug molecules in the active site and the interacting
residues.  The  selected  protein-drug  complexes  were  then  subjected  to  MD  simulation,  which
consists of various structural parameters to equivalently reflect their physiological state. From the
virtual screening results, two drug molecules were selected for each drug target protein [Paritaprevir
(ΔG = −9.8 kcal/mol) & Raltegravir (ΔG = −7.8 kcal/mol) for 3CLpro and Dolutegravir (ΔG = −9.4 
kcal/mol) and Bictegravir (ΔG = −8.4 kcal/mol) for 2′-OMTase]. After the extensive computational
analysis,  [the  authors]  proposed  that  Raltegravir,  Paritaprevir,  Bictegravir  and  Dolutegravir  are
excellent lead candidates for these crucial  proteins and they could become potential  therapeutic
drugs against SARS-CoV-2". Raltegravir is also considered in [11].
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